Laser light at home could ease nerve pain in feet
NCT ID NCT06912646
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests a portable laser device that people use at home to temporarily relieve foot pain caused by idiopathic peripheral neuropathy. 32 adults with constant foot pain for at least 3 months will use the device twice daily for 21 days. The main goal is to see if at least 30% of participants report a meaningful reduction in pain.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Erchonia EVRL handheld laser device (red and violet light)
- What this could lead to
- If it works, this could provide a drug-free option for temporary relief of nerve pain in the feet.
- What could go wrong
- This is a small, early-stage trial with only 32 people. The effect may be modest or no better than a placebo, and long-term benefits are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 32 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2025
- Expected to finish
-
Jun 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
22 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Previously diagnosed with idiopathic peripheral neuropathy by a suitably qualified and licensed health professional within the past 6 months. * Over the age of 22 years of age * Able to read and write English * Constant feet pain on-going over at least the past 3 months * Subjects using analgesics (pain medication) must be on a stable analgesic regimen (i.e., no changes to the prescribed analgesic regimen) over a period of at least 14 days prior to study enrollment; and be willing and able to not have planned upward dose titration of analgesics during the study period. Decreasing frequency of analgesic use during the study is permitted. Cannabis prescribed for medicinal purposes qualifies as an analgesic in this context * Willing and able to refrain from engaging in any non-study therapies for the management of foot pain throughout the course of study participation, including conventional therapies such as physical therapy, occupational therapy, hot or cold packs, and alternative therapies such as chiropractic care and acupuncture * Agrees to refrain from taking a dosage of analgesic (pain medication) for at least 6 hours before a scheduled VAS foot pain rating is to be recorded * Subject's degree of foot pain on the 0-100 VAS, with "0" being no pain and "100" being worst pain imaginable, is 50 or greater Exclusion Criteria: * Diabetic, referred to as having hemoglobin A1c (HbA1C) of 6.5% or higher * Previously diagnosed with any definitive (i.e. not idiopathic) cause of peripheral neuropathy by a suitably qualified and licensed health professional within the past 6 months, such as diabetes, injury, infection, toxins and poisons, alcoholism, medications such as chemotherapy, autoimmune disorders, etc.. * Pregnant or possibly pregnant, breastfeeding, or planning pregnancy during the intended course of study participation * Open wounds (sores, cuts, ulcers, etc.) on or around the treatment area on the feet * Cancerous growths or lesions on or around the treatment area on the feet * Difficulty with hand dexterity sufficient to negatively impact the ability to administer treatments with the laser such as from severe arthritis in the hands, Multiple Sclerosis, Cerebral Palsy, Parkinson's Disease, Huntington's Disease, etc.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Idiopathic peripheral neuropathy are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Franco & Co
RECRUITINGMiramar, Florida, 33025, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could your own stem cells heal your brain? new trial tests it
- Laughing gas linked to nerve damage in young users
- Simple exercises ease chemo nerve damage in new study
- New pill aims to stop chemo from stealing hearing
- Can closing your eyes help you walk better? new rehab trial for nerve disorder
- Simple exercises may improve balance and health in diabetic nerve damage